Literature DB >> 17186190

[Palliative and supportive therapy in cases of renal cell carcinoma].

M Kurosch1, S Buse, J Bedke, N Wagener, A Haferkamp, M Hohenfellner.   

Abstract

At the time of diagnosis, 25-30% of all patients with renal cell carcinoma already present with metastatic disease. Furthermore, 20-30% of patients with renal cell carcinoma will have progressive disease despite radical nephrectomy with complete tumor resection. In this review, we discuss the current therapeutic options for patients with metastatic renal cell carcinoma: These include palliative radical nephrectomy, surgery of metastasis, tumor embolisation and medical treatment options (e.g. immunotherapy, chemotherapy and targeted therapy), as well as supportive pain treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17186190     DOI: 10.1007/s00120-006-1268-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  47 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.

Authors:  Hans-Stefan Hofmann; Heinz Neef; Katharina Krohe; Petko Andreev; Rolf-Edgar Silber
Journal:  Eur Urol       Date:  2005-03-20       Impact factor: 20.096

Review 3.  The role of arterial embolization in renal cell carcinoma.

Authors:  D Kalman; E Varenhorst
Journal:  Scand J Urol Nephrol       Date:  1999-06

4.  Clinical study of brain metastasis of renal cell carcinoma.

Authors:  Y Harada; N Nonomura; M Kondo; K Nishimura; S Takahara; T Miki; A Okuyama
Journal:  Eur Urol       Date:  1999-09       Impact factor: 20.096

5.  Renal cell carcinoma metastatic to the pancreas: results of surgical management.

Authors:  T A Sohn; C J Yeo; J L Cameron; A Nakeeb; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

6.  Hepatic resection for metastatic renal tumors: is it worthwhile?

Authors:  A Alves; R Adam; P Majno; V Delvart; D Azoulay; D Castaing; H Bismuth
Journal:  Ann Surg Oncol       Date:  2003-07       Impact factor: 5.344

7.  Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.

Authors:  M Volm; M Kästel; J Mattern; T Efferth
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

8.  Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review.

Authors:  P C Kierney; J A van Heerden; J W Segura; A L Weaver
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

9.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

10.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Authors:  J Atzpodien; H Kirchner; U Jonas; L Bergmann; H Schott; H Heynemann; P Fornara; S A Loening; J Roigas; S C Müller; H Bodenstein; S Pomer; B Metzner; U Rebmann; R Oberneder; M Siebels; T Wandert; T Puchberger; M Reitz
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.